This warning shows up when the page has a very small width.
Development for smaller screens is underway, and only the main page is coded so far.
This does not reflect the final state of the site.
Development for smaller screens is underway, and only the main page is coded so far.
This does not reflect the final state of the site.
Our Valued Assets:
NB001
Fully humanized anti-B7H3 mAb confirms superior tumor cell killing in ADC modality
NB002
Fc engineered fully humanized novel anti-Tim3 mAb with unique binding and functional properties - differentiating from competitors
NB003
Fully humanized anti-CECAM-1 mAb exhibits its anti-tumor efficacy via enhancement of NK & CD8 T-cell effector function, reduction in tumor metastasis and polypoidization
NB005
Novel target with immune check-point function - potential to synergize with anti-PD1 therapy
NB303
NB303 is a fully humanized blocking mAb exhibits superior anti-tumor efficacy compared to competitors